Tempest Therapeutics (TPST) Other Operating Expenses (2015 - 2018)
Tempest Therapeutics (TPST) posted Other Operating Expenses of -$1.9 million for Q3 2018, down 1881.31% sequentially from $107000.0 in Q2 2018, and down 18960.0% YoY from N/an in Q3 2017.
Tempest Therapeutics (TPST) Other Operating Expenses (2015 - 2018) Analysis & Trends
Tempest Therapeutics has reported Other Operating Expenses for 4 years, with the latest figure at -$1.9 million in Q3 2018.
- Quarterly Other Operating Expenses fell 18960.0% year-over-year to -$1.9 million in Q3 2018, while the trailing twelve-month figure through Jun 2019 was -$1.9 million (down 106.31% YoY) and the FY2017 annual result came in at $28.1 million, up 420.63% from the prior year.
- Other Operating Expenses retreated to -$1.9 million in Q3 2018 per TPST's latest filing, from $107000.0 in the prior quarter.
- Over five years, Other Operating Expenses peaked at $27.5 million in Q4 2017 and troughed at -$1.9 million in Q3 2018.
- A 4-year average of $2.4 million and a median of $940000.0 in 2015 frame the typical range for Other Operating Expenses.
- The sharpest annual moves came in 2016 and 2018: Other Operating Expenses jumped 3260.0% in 2016, then slumped 18960.0% in 2018.
- Over 4 years, Other Operating Expenses stood at $1.2 million in 2015, then grew by 23.75% to $1.4 million in 2016, then soared by 1822.33% to $27.5 million in 2017, then slumped by 106.92% to -$1.9 million in 2018.
- According to Business Quant data, Other Operating Expenses over the past three periods registered -$1.9 million, $107000.0, and $2.6 million for Q3 2018, Q2 2018, and Q1 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | -1.91 Mn |
| Jun 30, 2018 | 107,000.00 |
| Mar 31, 2018 | 2.56 Mn |
| Dec 31, 2017 | 27.55 Mn |
| Sep 30, 2017 | -10,000.00 |
| Jun 30, 2017 | 274,000.00 |
| Mar 31, 2017 | 269,000.00 |
| Dec 31, 2016 | 1.43 Mn |
| Sep 30, 2016 | 1.56 Mn |
| Jun 30, 2016 | 1.23 Mn |
| Mar 31, 2016 | 1.18 Mn |
| Dec 31, 2015 | 1.16 Mn |
| Sep 30, 2015 | 940,000.00 |
| Jun 30, 2015 | 116,000.00 |
| Mar 31, 2015 | 35,000.00 |